Introduction
All-trans retinoic acid (tRA) is known to be a key regulator of growth and development in both the adult, from vitamin A deficient (VAD) animal studies, and in the embryo, from analysis of the teratogenic effects resulting from administration of exogenous tRA. 1, 2 Similarly, tRA induces differentiation and inhibits proliferation of certain cell types, including HL-60 leukemia 3 and F9 embryonal carcinoma cells. 4, 5 tRA is being explored as a differentiation therapy in cancer because it induces complete remission in acute promyelocytic leukemia (APL). 6 Unfortunately, APL patients receiving only tRA therapy eventually experience retinoid resistance and clinical relapse. 7, 8 At the molecular level, tRA is a ligand for the retinoic acid receptor, RAR, which also binds the RA isomer 9-cis-RA (9cRA). Related receptors, RXRs, bind 9cRA. 9, 10 The RARs and RXRs belong to the steroid/nuclear receptor superfamily, which also includes the thyroid (TR), vitamin D (VDR), glucocorticoid (GR), and estrogen (ER) receptors. Members of this Correspondence: SM Pemrick at her present address: Merck Research Laboratories, RY32-605, Rahway, NJ 07065-0900, USA; Fax: 518 392 6665 Received 25 April 1997; accepted 21 November 1997 superfamily are dimeric, ligand-inducible-transcription factors, which activate nuclear target genes by binding to specific DNA sequences, termed HREs, within the promoter region. HREs are arranged as palindromic or direct repeats (DR) of a hexad consensus sequence (PuGGTCA). The steroid receptors, such as GR and ER, bind as homodimers to palindromic HREs, whereas RAR, TR and VDR (the non-steroid receptors) form heterodimers with RXR and bind preferentially to DR HREs, each heterodimer selecting for a specific distance between hexad repeats (for review see Refs 11 and 12) .
To fine tune retinoid-induced gene regulation, there are RAR and RXR subtypes and numerous isoforms, which are conserved more across species than within a species. 11 One hypothesis states dimeric combinations of RAR and RXR subtypes and isoforms regulate subsets of RAREs to exert the pleiotropic effects of retinoids. 13 Approaches to explore this hypothesis have included: rational development of receptorspecific ligands (eg see Ref. 14) ; targeted disruption ('knockout') via homologous recombination of one or both alleles for a particular receptor subtype. 2, 15 In addition, receptor-based gene therapies could feasibly be developed to manipulate the threshold concentration of specific RXR-RAR heterodimers in cancers responsive to retinoids. For the chimera, RAR␣/VDR described here, the inducible ligand would be D 3 , eliminating acquired drug resistance due to the pharmacokinetic properties of retinoids.
Designing functional chimeric receptors can be a straightforward experiment because all hormone receptors possess a linearly arranged modular structure (regions A to E or F), conserved to varying degrees within each family. 16 For example, the chimera GR/TR, replaced the n-terminal A/B region of TR for that of GR, to enhance T 3 induction of transcriptional activation. 17 The most conserved region, the C or DNA-binding domain, has two zinc finger motifs, and recognizes the base pair sequence of the HRE. 18 In a now classical experiment, the glucocorticoid HRE became responsive to ␤-estradiol by replacing the C region of ER with that of GR. 19 Region E, the ligand-binding domain, is also involved in other structurally overlapping functions, [20] [21] [22] [23] [24] including transactivation 22 and dimerization. 23, 24 The receptor polarity of DR HREs, with RXR at the 5′ HRE half-site, plus the freedom of rotation about the hinge region of the 3′-dimeric partner, 25 suggests the ligandbinding domains of RAR, VDR, and TR may be functionally interchangeable. Indeed, the ligand-binding domain of TR can substitute for that of RAR to place both synthetic 25 and natural RAREs 26 under the control of T 3 . We describe in this report, the functional characteristics of the chimeric receptor RAR␣/VDR, and show in F9 cells that RAR␣/VDR can mediate the differentiation morphology in response to D 3 treatment, without disturbing retinoid responsiveness. We conclude RAR␣/VDR can be a 'tool' to pinpoint or to modulate gene pathways regulated by RARs, without inhibiting the functional penetrance of endogenous RARs. For RAR␣/VDR (Figure 2a) , the VDR-ligand-binding domain (PCR-amplified (sequence verified) cDNA of amino acids 123 to 427 with engineered BamHI sites at either end) was inserted into the corresponding cloning site of pSG5-RAR␣ (cDNA for amino acids 1 to 199) immediately 3′ of the codon for RAR residue 199. For RAR␣/ER, the ligand-binding domain of ER (cDNA for amino acids 302 to 395) replaced that of VDR in pSG5-RAR␣/VDR. The ER/RAR␣/ER construct had the C region of RAR␣ (cDNA for amino acids 88 to 153) replacing the C region of ER (cDNA for amino acids 185 to 250). 30 The plasmid, pSV2-neo, has been described previously. 31 Cell culture and generation of stable transfectants CV-1, COS-1, and F9 cells were maintained as described. 32, 33 The heat-inactivated fetal calf serum was charcoal-stripped for F9 cells and for CV-1 cells when ␤-estradiol was the ligand. In the latter case, the media was also phenol-free. F9 cells were cotransfected at a 9:1 ratio of pSG5-RAR␣/VDR or Bluescript IIKS to pSV2-neo for a total of 20 g plasmid DNA per 2 × 10 6 cells (100 mm culture plate) using the calcium phosphate precipitation method. 34 G418-sulfate selection pressure (400 g/ml) was applied after one cell passage. Neomycin resistant clones were grown up in mass cultures 
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Materials
RNA preparation and Northern analysis
Total RNA was extracted from F9 cells by the guanidine isothiocyanate procedure (RNAzol B; Biotecx Laboratories, Houston, TX, USA). For Northern analysis, total RNA (20-30 g) from F9 clones was size fractionated on 1% agarose/6% formaldehyde gels in 20 mM MOPS (pH 7.0 HCl), 50 mM Na 2 EDTA, 5 mM sodium acetate and transferred to Gene Screen nylon membranes (DuPont-NEN). The RNA blots were hybridized (at 42°C) with a random primer labeled cDNA probe (Boehringer Mannheim Random Primed DNA Labeling Kit; Indianapolis, IN, USA), for the ligand-binding domain of VDR (Figure 2a ), which had been purified on G50 sephadex Quick Spin Columns (Boehringer Mannheim). Washed blots were exposed to Kodak X-Omat film with an intensifying screen at −80°C, for varying amounts of time.
COS-1 cells: nucleosol fractions and ligand-binding assays pSG5 expression vectors for RAR␣, and the chimeras were transfected into COS-1 cells by electroporation. 9 Nucleosol fractions were prepared 72 h after transfection and stored at −80°C. 32, 35 Receptor ligand-binding assays of nucleosol fractions have been described in detail elsewhere, 9,32 and involved either FPLC size exclusion chromatography or PD10 (Pharmacia, Uppsala, Sweden) desalting columns. Data analysis of saturation kinetics followed the method of Scatchard 36 as described previously. 9, 37 Transactivation assays in CV-1 cells
The procedures for transient cotransfection of CV-1 cells, ligand incubations (36 h), preparation and analysis of cell lysates have been described previously. 38 All cotransfections contained 0.5 g receptor expression plasmid, 5 g reporter plasmid (eg ␤(RARE) 3 -TK-LUC), 5 g control plasmid-, p␤Ac-lacZ, 4-5 g carrier plasmid-Bluescript IIKS, for a total of 15 g per 100 mm plate. Ligand-mediated transcriptional activity was expressed as either fold induction of normalized luciferase activity above that observed in the absence of ligand, or as a percentage of maximal normalized response. Co-immunoprecipitation of RXR␣ heterodimers with RXR␣ antibody RAR␣ and chimeric receptor cDNA were transcribed in vitro into capped mRNA using the mCAP kit (Stratagene) with T3 polymerase. Purified mRNA was translated in vitro using rabbit reticulocyte lysates (Promega) in the presence of 35 S-methionine. 39, 40 Construction of a baculovirus containing RXR␣ cDNA and preparation of RXR nucleosol fractions have been described. 41 Affinity purified rabbit antibody was directed to a 22 amino acid sequence of the D domain of RXR␣. 41 To measure RXR heterodimer formation, nuclear extract containing RXR␣ (125 ng protein) was incubated with 35 S-labeled in vitro translated RAR␣ or its chimeras, in 100 l buffer A (20 mM N-2 hydroxyethylpiperazine-N′-2-ethanesulfonic acid HEPES, pH 7.9), 50 mM NaCl, 1 mM Na 2 EDTA, 5% glycerol, 0.05% Triton X-100 plus 0.5% BSA (w/v) for 1 h (4°C), followed by incubation with RXR␣-specific antibody or normal serum for 16 h (4°C). Samples were further incubated (2 h) with pre-washed protein A-agarose beads (15 l; Boehringer Mannheim), and washed in buffer A plus and minus 0.1% BSA. Bound material was eluted in SDS-PAGE sample buffer and analyzed on 8% polyacrylamide gels. 42 Gels were processed for fluorography, impregnated with Enlightening (Dupont-NEN), dried and exposed to film. 40 Gel mobility shift assays COS-1 cells were transfected by the DEAE-dextran procedure with 10 g each of pSG5 (Control) or receptor expression vectors. Whole cell extracts were prepared, 38, 43 and protein concentration determined 44 using a commercial Bradford reagent (BioRad, Richmond, VA, USA). Cells transfected with pSG5-RAR␣/ER or pSG5-ER/RAR␣/ER were treated with 10 −8 M ␤-estradiol for 1 h before harvesting. The RARE oligonucleotide 27 was labeled by filling in the 5′ overhangs with dATP, dTTP, dGTP and ␣-32 P dCTP using the Klenow fragment of E. coli DNA polymerase 1. Specific competitor oligonucleotides were prepared similarly, but with unlabeled dCTP. Nonspecific competitor oligonucleotides consisted of two copies of a consensus DNA-binding site for the p53 protein. 45, 46 The preincubation and incubation protocols for the whole cell extracts and RXR were as described in detail elsewhere. 38 Protein-DNA complexes were resolved on a native 5% (acrylamide-N,N′-methylenebisacrylamide 29:1) polyacrylamide gel (2 h at 20 mA). Gels were dried (1 h at 80°C) and exposed to film as described above.
Results
RAR␣/VDR binds D 3 with high affinity and specificity
Nucleosol fractions from RAR␣/VDR transfected COS-1 cells, were treated (4 h, 4°C) with 3 H D 3 and analyzed by sizeexclusion FPLC. The elution profile consists of one radioactive peak at 25.3 min, corresponding to the predicted molecular weight of 56.4 kDa for RAR␣/VDR. VDR, however, elutes at 25.9 min because of a lower predicted molecular weight (48.3 kDa). In the presence of a 100-fold molar excess of unlabeled ligand, the elution profile is flat providing no evidence for nonspecific binding of D 3 to either RAR␣/VDR or VDR (data not shown).
The principles of saturation kinetics were used to quantitate the affinity of D 3 for VDR-and for RAR␣/VDR-enriched nucleosol fractions (Figure 1 ). This approach confirms minimal nonspecific binding of D 3 and similar expression levels for both VDR and RAR␣/VDR (Figure 1a and b) . Scatchard analyses (Figure 1c and d fold by 100 nM D 3 . The half-maximal induction value was not calculated with the RXRE because of the shallow transactivation profile. A similar response element selectivity is observed for RAR␣ in the presence of tRA (see below and in Table 1 ).
Comparison of RAR␣/VDR with RAR␣/ER and ER/RAR␣/ER Both RAR chimeras with ER ligand-binding domains bind 3 H-␤-estradiol and exhibit a retention profile by size exclusion FPLC similar to that of ER (not shown). Neither RAR␣/ER nor ER/RAR␣/ER, can induce ␤-estradiol-mediated transactivation from the RARE ( Table 1 ). This inactivity is not due to the cellular milieu of CV-1 cells. Wild-type ER, when expressed in CV-1 cells is capable of five-fold induction of ␤-estradiolmediated transactivation from an ERE reporter gene (not shown).
Ability to form heterodimers with RXR
In a representative experiment, the ability of the three chimeras to form heterodimers with RXR␣ was compared with RAR␣. Figure 3 shows RAR␣ and RAR␣/VDR form heterodimers with RXR␣; whereas, RAR␣/ER and ER/RAR␣/ER fail to heterodimerize with RXR␣. Noticeably, the amount of the heterodimer complex is greater for RAR␣ than for RAR␣/VDR. Increasing the autoradiograph exposure time from 3 h (Figure 3 ) to 16 h (not shown) gives an additional weak signal indicating possible heterodimer formation for RAR␣/ER, but not for ER/RAR␣/ER.
Ability to bind to a RARE
The relative ability of the receptors, ER and RAR␣, vs the chimeras, to bind to a RARE was determined by the gel mobility shift assay. Figure 4 shows only RAR␣ and RAR␣/VDR bind to the RARE. The specificity of this binding Gel mobility shift assay (EMSA) comparing the relative ability of ER and RAR␣ vs the chimeras, to bind to the ␤RARE. Only RAR␣ (␣) and RAR␣/VDR (␣-V) bind to the 32 P-labeled RARE probe; binding is specific as determined by the ability of a 100-fold excess of unlabeled RARE (S oligo), but not nonspecific oligo (N oligo) to eliminate detection of a labelled receptor-RARE complex. Binding to the RARE performed in 150 mM KCl with 32 P-␤RARE probe in the absence (C) or presence of either pSG5 (M, mock) ER, ER/RAR␣/ER (E-␣-E), RAR␣/ER (␣-E), ␣,or ␣-V transfected COS-1 whole cell extracts (0.5 g + 0.5 g RXR␣). Representative autoradiograph of PAGE in 5% gels. is demonstrated by the ability of a 100-fold excess of unlabeled RARE oligo, but not a nonspecific oligo, to eliminate the radioactive signal. This experiment was performed with whole cell extracts from transiently transfected COS-1 cells, which also contain endogenous RXR␣. Binding to the RARE was measured both in the presence (Figure 4 ) and absence (data not shown) of exogenous RXR␣. In both cases, RAR␣ and RAR␣/VDR form only one type of complex (heterodimer) on the RARE; ER and ER/RAR␣/ER do not bind to the RARE. However, RAR␣/ER gives some indication of binding to the RARE under low stringency conditions and high chimera concentrations (data not shown).
Transcriptional activity from a variety of HREs
In Table 1 , RAR␣ and RXR␣ are compared with the chimeras for the ability to induce ligand-mediated transcriptional activation from the following HREs: DR-5 (␤(RARE) 3 ); DR-2
Figure 7
Changes in proliferation of F9 wild-type (F9-Wt) and F9-neo-RAR␣/VDR cells from 0 to 96 h after treatment with either ethanol (0), tRA (RA) or D 3 (D3) in the presence of dibutyryl cAMP and theophylline. Drug concentrations are provided in Figure 6. (RXREs, ApoA1 and CRBP II); palindromic (TREpal and (TRE3) 3 ). In general, the activity profile of RAR␣/VDR follows most closely that of RAR␣ on the various HREs. Both RAR␣ and RAR␣/VDR are considerably active on the RARE, relatively inactive on the RXREs, and marginally active on the palindromic HREs. However, RAR␣/VDR is only one-third as active as RAR␣ from the TREpal reporter gene. RAR␣/ER and ER/RAR␣/ER, on the other hand, are relatively inactive on DR HREs, but can be active on palindromic HREs. For example, ER/RAR␣/ER is transcriptionally active from both palindromic HREs, whereas RAR␣/ER is active only from the (TRE3) 3 reporter gene. RXR␣ appears to be maximally active, not only from RXREs, but also, from the palindromic HREs. However, the absolute value of ligand-mediated transactivation induced by RXR␣ is much less on the TREs, compared with the RXREs (three-vs 25-fold induction, respectively).
Qualitative analysis of the biological activity of RAR␣/VDR Stable transfectant F9 cell lines were generated which contain either the neomycin gene alone (F9-neo), or together with the RAR␣/VDR gene (F9-neo-RAR␣/VDR). Figure 5 shows a Northern analysis of total RNA from the above F9 cell lines probed for the VDR-ligand-binding domain transcript. Only F9-neo-RAR␣/VDR cells exhibit a radioactive RNA species migrating at 2500 bps, as expected for RAR␣/VDR mRNA. There is no indication, even after exposure times as long as 2 weeks, that VDR mRNA is expressed in F9-Wt cells ( Figure 5 and data not shown).
In the presence of tRA, F9 cells differentiate into either parietal or primitive endodermal cells depending upon the pres-ence or absence of dibutyryl cAMP, respectively. Spontaneous differentiation is negligible and not enhanced by dibutyryl cAMP alone. As shown in Figure 6a and d, both F9-Wt and F9-neo-RAR␣/VDR cells retain the compact morphology of undifferentiated cells 96 h after treatment with 250 M dibutyryl cAMP and 500 M theophylline. Four days after treatment with 1 M tRA (plus dibutyryl cAMP and theophylline), both F9-Wt and F9-neo-RAR␣/VDR cells differentiate morphologically into parietal endodermal cells, characterized by long cellular processes, rounded cell shape with distinct borders, and an increase in distance between cells (Figure 6b and e) . Critical to the present study, when 1 M tRA is replaced by 30-100 nM D 3 in the above treatment protocol, F9-neo-RAR␣/VDR cells differentiate into parietal endodermal cells ( Figure 6f) ; whereas, the F9-Wt cells retain the compact morphology of undifferentiated cells (Figure 6c ).
In the presence of nontoxic concentrations of tRA (ie 1-500 M), 47 the growth rate of F9-Wt cells decreases concomitant with differentiation. In Figure 7 , this antiproliferative effect of tRA is compared with the effect of D 3 for F9-Wt vs F9-neo-RAR␣/VDR cells. Four days following drug treatment, tRA decreases by 50-60% the growth rate of both F9-Wt and F9-neo-RAR␣/VDR cells. D 3 , however, has no effect upon the growth rate of F9-Wt cells, but decreases by approximately 55% the growth rate of F9-neo-RAR␣/VDR cells, similar to that observed in the presence of tRA for both F9-Wt and F9-neo-RAR␣/VDR cells.
Discussion
The present study analyzed the properties of RAR␣/VDR in three cellular systems (COS-1, CV-1, F9) to conclude that both RAR␣/VDR and RAR␣ exhibit similar fold-induction of ligandmediated transcriptional activation from a variety of HREs ( Figure 2b and Table 1 ), form heterodimers with RXR (Figure 3 ), bind to the RARE (Figure 4 ) and induce ligandmediated differentiation in F9 cells (Figures 6 and 7) . Besides the obvious heterologous ligand-binding domain, RAR␣/VDR differs from RAR␣ in two minor respects: less active from the TREpal reporter gene (Table 1) ; weaker RXR-binding properties under equilibrium binding conditions (Figure 3 ). Others 48 have observed that RXR heterodimers which are unstable under in vitro assay conditions may be sufficiently stable in vivo to induce gene transcription. This is obviously the case for RXR-RAR␣/VDR in F9 cells (Figures 6 and 7) . It remains to be determined whether RAR␣/VDR is functional in a wide variety of model systems. For example, in NB4 cells, an APL model system, RAR␣/VDR would have to successfully compete against PML/RAR␣ for RXR. This may require relatively high RAR␣/VDR expression levels depending upon the relative stability of RXR-PML/RAR␣ vs RXR-RAR␣/VDR in vivo.
The chimeras, RAR␣/ER and ER/RAR␣/ER, were analyzed to test the general applicability of swapping ligand-binding domains between nuclear receptors, without destroying transcriptional activation. We conclude neither RAR chimera with an ER ligand-binding domain is capable of substituting for RAR␣ in cellular systems (this study, and JF Grippo, unpublished data in F9 cells). Even though RAR␣/ER 49 and ER/RAR␣/ER can be active from palindromic HREs, neither is active from the preferred HRE of RAR␣, ␤(RARE) 3 (Table 1 ). In the case of RAR (VDR or TR), the DR HRE correctly positions dimerization interfaces within the DNA-and ligand-binding domains to within close proximity of specific interfaces on RXR.
12,23 For RAR␣/ER and ER/RAR␣/ER, correct alignment of dimerization interfaces is improbable, because ER does not heterodimerize with RXR, but instead forms ER homodimers, which selectively bind to palindromic HREs. In fact, the target DNA (HRE) acts as a necessary allosteric activator of recognition for steroid receptor homodimers. 50 It was not surprising, therefore, that ER/RAR␣/ER and RAR␣/ER were transcriptionally inactive from DR HREs (Table 1) , even though under certain conditions RAR␣/ER (but not ER/RAR␣/ER) could bind to RXR␣ and to the RARE, albeit to a much lesser degree than either RAR␣ or RAR␣/VDR (see Results).
Unliganded RAR, and the unliganded chimeras can inhibit ligand-mediated transcriptional activation by other RARs on ␤(RARE) 3 -TK-LUC.
51 Dominant-negative activity by unliganded receptors was not an artefact due to squelching of general transcription factors, 52 because inhibition was relieved by increasing the concentration of expression plasmid for the liganded receptor (SM Pemrick, unpublished observations). Dominant-negative activity has been observed by mutated RARs, 53, 54 PML/RAR␣, 55 and by native RARs in the presence of nuclear receptor co-repressors, [56] [57] [58] that shift the equilibrium of unliganded receptors toward the repressive state. 58 Obviously, overexpression of RAR␣/VDR in F9 cells could conceivably, in the absence of D 3 , suppress RAR-mediated gene pathways. 52, [56] [57] [58] For this reason, the differentiation experiments ( Figures 6 and 7) were performed on F9-neo-RAR␣/VDR cell lines with low expression levels of the chimeric receptor gene (ie line 1,2B in Figure 5 ). Fortunately, this concern may be unwarranted, because we were able to generate healthy RAR␣/VDR mouse lines which overexpressed the RAR␣/VDR transgene. 59 The goal of genetic experiments which disrupt or 'knockout' both alleles of one or two RAR isoforms 2, 15, 60, 61 is to assign specific tRA-mediated effects and gene pathways to specific RAR isoforms. What has been achieved, however, provides evidence for functional redundancy or receptor recruitment among the isoforms. 2, 60, 62 In contrast, the chimeric receptor approach attempts to induce RAR-mediated effects by a ligand unrelated to tRA without disturbing retinoid responsiveness (see Figures 6 and 7) , and derepress or augment ligandmediated gene transcription induced by RARs. Both experimental strategies are complementary, yielding similar general interpretations.
The usefulness of RAR␣/VDR as a biological probe is most obvious for, but not restricted to, cells and tissues which do not express VDR or respond to D 3 . For example, U937 (monocytic), HL-60 (myelocytic) and THP-1 (mature monocytic) cells differentiate in response to either tRA or D 3 . In general, D 3 causes monocytic differentiation, which can be potentiated by TGF-␤ 1 ; 63 whereas, tRA causes granulocytic differentiation. 64 Expression of PML/RAR␣ in mutant U937 cells blocks specifically the ability of D 3 alone or combined with TGF-B 1 to induce differentiation. 65 NB4 cells express PML/RAR␣ and possibly VDR, 66 but respond poorly to D 3 .
66,67
Recent evidence suggests any D 3 effects in NB4 cells are independent of nuclear receptor binding. 68 The subline NB4.306, is resistant to both tRA and D 3 , 66 and does not express a functional PML/RAR␣. 69 However, NB4.306 cells do express RAR␣ and appear to retain some responsiveness to tRA, such as CD18 expression. 69 These findings suggest RAR␣/VDR is likely to be an useful experimental tool in tRA-sensitive and possibly tRA-resistant NB4 cells to probe gene pathways regulated by RAR␣.
The potential usefulness of RAR␣/VDR as a gene therapy is not limited to cells and tissues unresponsive to D 3 . In mammalian cells, overexpression of targeted genes by foreign nuclear receptors such as the insect ecdysone receptor, 70 and by chimeric receptors such as RAR␣/VDR, offers considerable potential as part of gene therapy strategies to control cancer. Adapting gene therapy technologies 71 to induce cell lineagespecific terminal differentiation and apoptosis could represent a major advance in cancer therapy. For example, this technique may make it possible to derepress RAR-induced gene pathways, to trigger terminal differentiation or growth inhibition of a wide variety of neoplastic lesions.
We suggest RAR␣/VDR be explored initially as a gene therapy in retinoid-responsive leukemias (eg APL or acute myelogenous leukemia (AML)) for the following reasons. Firstly, this exploration is now feasible. A number of gene therapy strategies aimed at increasing the survival of leukemia patients have entered clinical trials. 72 In AML, ex vivo transfer of a marker gene (neomycin) to stem cells in marrow, has been successful for up to 3 years. 73, 74 Secondly, D 3 analogs have been developed which minimize the undesirable pharmacodynamic effects of the vitamin. 75 The present characterization of RAR␣/VDR, therefore, provides the necessary experimental foundation for future research to develop RAR␣/VDR as a gene therapy in retinoid responsiveness neoplasms.
